Director Sara R. May filed a Form 4 with the SEC on November 17, 2026, disclosing the acquisition of 5,813 common shares of Medicus Pharma Ltd. through a private placement transaction dated November 13, 2026.

Key Highlights

  • Reporting person: Sara R. May, identified as a Director of Medicus Pharma Ltd.
  • Transaction date: November 13, 2026, via a subscription agreement with the issuer.
  • Shares acquired: 5,813 common shares, no par value, with transaction code "A" (acquired).
  • Purchase price: $1.72 per share in a private placement.
  • Resulting ownership: 5,813 common shares beneficially owned directly following the transaction.
  • Other participants: According to the filing, other investors also participated under separate subscription agreements in the same private placement.

Medicus Pharma Director Enters Subscription Agreement in Private Placement

According to the Form 4 filed on November 17, 2026, Sara R. May, a director of Medicus Pharma Ltd. (NASDAQ:MDCX), acquired 5,813 common shares, no par value, at a purchase price of $1.72 per share. The filing identifies the transaction code as "A," indicating an acquisition, with an earliest transaction date of November 13, 2026.

The filing's explanation of responses states: "On November 13, 2026, Sara R. May entered into a subscription agreement with the Issuer, pursuant to which Ms. May agreed to purchase 5,813 common shares, no par value, at a purchase price of $1.72 per share in a private placement in which other investors also participated under separate subscription agreements." The form was signed by Raza Bokhari as Attorney-in-Fact for Sara R. May and filed on November 17, 2026.

Following the reported transaction, the filing discloses that May directly and beneficially owns 5,813 common shares. No derivative securities are reported in Table II of the filing. The form was filed by one reporting person and indicates no amendment to a prior filing.

What Was Disclosed

The filing reports a single acquisition by Director Sara R. May of 5,813 Medicus Pharma common shares at $1.72 each through a November 13, 2026 subscription agreement in a private placement. Total direct beneficial ownership following the transaction is 5,813 shares.